Cervical Cancer Diagnostics Market - Global Industry Perspective, Comprehensive Analysis and Forecast 2020-2026

According to the report, global demand for cervical cancer diagnostics market was valued at approximately USD 8,816.6 Million in 2019, and is expected to generate revenue of around USD 12,996.4 Million by end of 2026, growing at a CAGR of around 5.7% between 2020 and 2026.

Cancer is a group of diseases involving abnormalgrowth of cellswith the potential to spread to other parts of the body. There are various types of cancers affecting different parts of body. Cancer which develops in cervix is called cervical cancer. Two major types of cervical cancers diagnosed in women include adenocarcinoma and squamous cell carcinoma. Almost all types of cervical cancer are caused by human papiloma virus (HPV). Cervical cancer is the third most common cancer among women and the second most frequent cause of cancer-related death, accounting for almost 3,00,000 deaths annually. Diagnosis of cervical cancer is done by Pap Smear Tests, Colposcopy, HPV Testing, Endocervical Curettage (ECC). Cervical cancer is a sexually transmitted disease that can be prevented by early detection and vaccination.

Cervical cancer diagnostics market is driven majorly by increasing percentage of HPV infected people across globe. HPV is an extremely common virus. According to theCenters for Disease Control and Prevention(CDC), six million people in the United States acquire HPV each year. At least 20 million already have it, and more than half of all sexually-active adults are expected to be infected during their lifetime. Furthermore, rising awareness, literacy rate, government initiatives, government funding and various screening methods are expected to increase the growth of the market over the years. Moreover, many lifestyle-related factors, such as having multiple sex partners, smoking, obesity, unsafe sex and inherited HPV positive patients, are estimated to drive the cervical diagnostics market in the near future.However prevention of HPV by vaccination is major restraining factor in the growth of cervical cancer diagnostics market. In addition to this, the uncertain returning policy serves to be a major challenge impacting the growthof cervical cancer diagnostics market.

The report covers forecast and analysis of the cervical cancer diagnostics market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million). To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the cervical cancer diagnostics market has also been included in the study. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides detailed segmentation of the cervical cancer diagnostics market based on application and region. The regional market segment held the largest market share in 2015.

Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global cervical cancer diagnostic market in 2015 on account of the rising incidence of HPV infection, rising number of women smokers, and growing aged population. North America was followed by Europe in 2015. The market is expected to witness the growth in the Asia-Pacific region in the coming years due to the rising HPV infection in population, government initiative and availability of advance health care infrastructure.

Some of the key players contributing to the cervical cancer diagnostics market are Abbott Laboratories, Qiagen N.V., Hologic Inc., Roche Diagnostics, Quest Diagnostics, Becton, Dickinson and Company

This report segments the cervical cancer diagnostics market are follows:-

Cervical Cancer Diagnostics Market: Application Analysis

Pap Smear Tests
Colposcopy
HPV Testing

Cervical Cancer Diagnostics Market: Regional Analysis

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Chapter 1. Preface
- 1.1. Report Description and Scope
- 1.2. Research Scope
- 1.3. Research Methodology
  - 1.3.1. Market Research Process
  - 1.3.2. Market Research Methodology
Chapter 2. Executive Summary
- 2.1. Cervical Cancer Diagnostics Market, 2016 – 2026 (USD Million)
- 2.2. Cervical Cancer Diagnostics Market: Snapshot
Chapter 3. Cervical Cancer Diagnostics Market – Industry Analysis
- 3.1. Cervical Cancer Diagnostics Market: Market Dynamics
- 3.2. Market Drivers
  - 3.2.1. Growing incidence of cervical cancer in middle-aged women
  - 3.2.2. Increasing number of awareness programs for cervical cancer screening
- 3.3. Restraints
  - 3.3.1. Changes in regulatory guidelines for cervical cancer screening
- 3.4. Opportunities
- 3.5. Porter’s Five Forces Analysis
- 3.6. Market Attractiveness Analysis
  - 3.6.1. Market attractiveness analysis by Test Type
  - 3.6.2. Market attractiveness analysis by Region
Chapter 4. Cervical Cancer Diagnostics Market– Competitive Landscape
- 4.1. Company market share analysis
  - 4.1.1. Global Cervical Cancer Diagnostics Market: company market share, 2019
- 4.2. Strategic development
  - 4.2.1. Acquisitions & mergers
  - 4.2.2. New product launches
  - 4.2.3. Agreements, partnerships, collaborations and joint ventures
  - 4.2.4. Research and development and regional expansion
Chapter 5. Global Cervical Cancer Diagnostics Market – Test Type Analysis
- 5.1. Global Cervical Cancer Diagnostics Market overview: by Test Type
  - 5.1.1. Global Cervical Cancer Diagnostics Market share, by Test Type, 2019 and 2026
- 5.2. Pap Testing (Cytulogy Testing)
  - 5.2.1. Global Cervical Cancer Diagnostics Market by Pap Testing (Cytulogy Testing), 2016 – 2026 (USD Million)
- 5.3. HPV Testing
  - 5.3.1. Global Cervical Cancer Diagnostics Market by HPV Testing, 2016 – 2026 (USD Million)
- 5.4. Culposcopy
  - 5.4.1. Global Cervical Cancer Diagnostics Market by Culposcopy, 2016 – 2026 (USD Million)
- 5.5. Cervical Biopsies
  - 5.5.1. Global Cervical Cancer Diagnostics Market by Cervical Biopsies, 2016 – 2026 (USD Million)
- 5.6. Cystoscopy
  - 5.6.1. Global Cervical Cancer Diagnostics Market by Cystoscopy, 2016 – 2026 (USD Million)
Chapter 6. Global Cervical Cancer Diagnostics Market - Regional Analysis
- 6.1. Global Cervical Cancer Diagnostics Market overview: by Region
  - 6.1.1. Global Cervical Cancer Diagnostics Market share, by Region, 2019 and 2026
- 6.2. North America
  - 6.2.1. North America Cervical Cancer Diagnostics Market, 2016 – 2026 (USD Million)
  - 6.2.2. North America Cervical Cancer Diagnostics Market revenue, by Country, 2016 – 2026 (USD Million)
  - 6.2.3. North America Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.2.4. U.S.
    - 6.2.4.1. U.S. Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.2.5. Rest of North America
    - 6.2.5.1. Rest of North America Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
- 6.3. Europe
  - 6.3.1. Europe Cervical Cancer Diagnostics Market, 2016 – 2026 (USD Million)
  - 6.3.2. Europe Cervical Cancer Diagnostics Market revenue, by Country, 2016 – 2026 (USD Million)
  - 6.3.3. Europe Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.3.4. U.K.
    - 6.3.4.1. U.K. Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.3.5. France
    - 6.3.5.1. France Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.3.6. Germany
    - 6.3.6.1. Germany Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.3.7. Rest of Europe
    - 6.3.7.1. Rest of Europe Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
- 6.4. Asia Pacific
  - 6.4.1. Asia Pacific Cervical Cancer Diagnostics Market, 2016 – 2026 (USD Million)
  - 6.4.2. Asia Pacific Cervical Cancer Diagnostics Market revenue, by Country, 2016 – 2026 (USD Million)
  - 6.4.3. Asia Pacific Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.4.4. China
    - 6.4.4.1. China Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.4.5. Japan
    - 6.4.5.1. Japan Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.4.6. India
    - 6.4.6.1. India Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.4.7. Rest of Asia Pacific
    - 6.4.7.1. Rest of Asia Pacific Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
- 6.5. Latin America
  - 6.5.1. Latin America Cervical Cancer Diagnostics Market, 2016 – 2026 (USD Million)
  - 6.5.2. Latin America Cervical Cancer Diagnostics Market revenue, by Country, 2016 – 2026 (USD Million)
  - 6.5.3. Latin America Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.5.4. Brazil
    - 6.5.4.1. Brazil Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.5.5. Rest of Latin America
    - 6.5.5.1. Rest of Latin America Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
- 6.6. The Middle East and Africa
  - 6.6.1. The Middle East and Africa Cervical Cancer Diagnostics Market, 2016 – 2026 (USD Million)
  - 6.6.2. The Middle East and Africa Cervical Cancer Diagnostics Market revenue, by Country, 2016 – 2026 (USD Million)
  - 6.6.3. The Middle East and Africa Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.6.4. GCC Countries
    - 6.6.4.1. GCC Countries Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
  - 6.6.5. Rest of Middle East & Africa
    - 6.6.5.1. Rest of Middle East & Africa Cervical Cancer Diagnostics Market revenue, by Test Type, 2016 – 2026 (USD Million)
Chapter 7. Company Profiles
- 7.1. Abbott Laboratories
  - 7.1.1. Overview
  - 7.1.2. Financials
  - 7.1.3. Product portfolio
  - 7.1.4. Business Strategy
  - 7.1.5. Recent Developments
- 7.2. Qiagen N.V.
  - 7.2.1. Overview
  - 7.2.2. Financials
  - 7.2.3. Product portfolio
  - 7.2.4. Business Strategy
  - 7.2.5. Recent Developments
- 7.3. Hulogic Inc.
  - 7.3.1. Overview
  - 7.3.2. Financials
  - 7.3.3. Product portfolio
  - 7.3.4. Business Strategy
  - 7.3.5. Recent Developments
- 7.4. Roche Diagnostics
  - 7.4.1. Overview
  - 7.4.2. Financials
  - 7.4.3. Product portfolio
  - 7.4.4. Business Strategy
  - 7.4.5. Recent Developments
- 7.5. Quest Diagnostics
  - 7.5.1. Overview
  - 7.5.2. Financials
  - 7.5.3. Product portfolio
  - 7.5.4. Business Strategy
  - 7.5.5. Recent Development
- 7.6. Becton, Dickinson and Company
  - 7.6.1. Overview
  - 7.6.2. Financials
  - 7.6.3. Product portfolio
  - 7.6.4. Business Strategy
  - 7.6.5. Recent Development